UPDATE 2-China says talks to include Paxlovid in its health insurance drug list fail
(Provides Pfizer remark in 5th paragraph) BEIJING, Jan 8 (Reuters) – China will not contain Pfizer Inc’s Paxlovid in an update to its listing of medicines covered by primary clinical insurance plan schemes as the U.S. agency quoted a substantial price tag for the COVID-19 drug, China’s Healthcare Safety Administration (NHSA) explained on Sunday. The COVID-19 antiviral drug is at the moment protected by the country’s wide health care insurance plan plan less than short-term steps the regulator introduced in…
